RSS

Type 2 diabetes

In the next 12 years, half of those with type 2 diabetes won’t be able to receive potentially life-saving insulin unless access to the drug improves, new research shows. Read more

News

A clinical study, performed by researchers from the UK and China, has demonstrated that novel triple receptor agonists (TAs) originally developed to treat Type 2 diabetes, significantly reversed memory loss in a mouse model of Alzheimer’s disease. Read more

News

A post-hoc analysis, recently presented during the annual meeting of the European Association for the Study of Diabetes, has demonstrated that Xultophy significantly reduced a number of risk factors associated with CVD in diabetic patients Read more

News

An analysis of the LEADER trial, evaluating the long-term effects of Victoza (liraglutide), has shown that the treatment reduces the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk. Read more

News

Crown Bioscience has announced the publication of two new scientific papers indicating that the FATZO model is a significantly improved rodent model for obesity, dysmetabolism and type 2 diabetes for pre-clinical studies. Read more

News

The collaboration between Eli Lilly and Company and KeyBioscience will focus on developing a potential new class of treatments for metabolic disorders, such as type 2 diabetes, called dual amylin calcitonin receptor agonists (DACRAs) Read more

News

Analyst company GBI Research has concluded that due to an increasing demand for type 2 diabetes mellitus (T2DM) therapeutics, there is a large and competitive market landscape. Read more

News

Drug discovery company, Crown Bioscience, has made progress in developing a model of non-alcoholic fatty liver disease (NAFLD). Read more

News

New collaboration between Sanofi and Verily Life Sciences aims to help people with diabetes live full, healthy lives. Read more

News

Sanofi and the life sciences team at Google are teaming up to improve care and outcomes for people with type 1 and type 2 diabetes Read more

News

The Ministry of Health, Labor and Welfare in Japan has granted marketing authorisation for Sanofi's insulin glargine [rDNA origin] injection, 300 u/ml, a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus. Read more

News

A three-year research collaboration will see AstraZeneca and the French National Institute of Health and Medical Research investigate new therapeutic approaches to type 2 diabetes and chronic kidney disease. Read more

News

New findings showed that adults with type 2 diabetes treated with Victoza, in combination with metformin, experienced similar improvements in blood glucose control while fasting during Ramadan compared with sulfonylurea plus metformin. Read more

News

Novo Nordisk has announced that CHMP has adopted a positive opinion for Xultophy, the first ever once-daily basal insulin and GLP-1 analogue in one pen. Read more

Aesica’s High Capacity Manufacturing facility has been validated for commercial production; $45 million (€32.4/£27 million) has been invested at its Queenborough, UK, site. Read more

Technology

Aesica has announced the creation of a new High Capacity Manufacturing Facility following a £30 million investment at its Queenborough, Kent site. The 10,000 m2 expansion has been constructed for the production of a solid dose medication used in... Read more

Technology